UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis

Annals of oncology, 2016-10, Vol.27, p.vi291-vi291

2016

Volltextzugriff (PDF)

A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

Canadian Urological Association journal, 2018-02, Vol.12 (2), p.E47-52

2018

Volltextzugriff (PDF)

7170 Clinical practice guideline impact on referral and treatment rates of neoadjuvant chemotherapy for muscle-invasive bladder cancer: a comparative analysis between two Canadian tertiary care centres

European journal of cancer supplements, 2009, Vol.7 (2), p.444-444

2009

Volltextzugriff (PDF)

Cost of care for prostate cancer patients: An observational cohort study comparing clinical trials to standard care

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.184-184

2011

Volltextzugriff (PDF)

7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC)

European journal of cancer supplements, 2009, Vol.7 (2), p.407-407

2009

Volltextzugriff (PDF)

A randomized, double-blind, placebo-controlled, phase 3 trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 genetic alterations: PROOF 302

European urology open science (Online), 2021-11, Vol.33, p.S370-S371

2021

Volltextzugriff (PDF)

Measurable Absolute Basophil Count is Associated with Progression to Muscle Invasive Disease in Patients with High-Grade Non-Muscle Invasive Bladder Cancer

Urologic oncology, 2020-12, Vol.38 (12), p.902-902

2020

Volltextzugriff (PDF)

Do clinical practice guidelines (CPGs) change clinical practice? An analysis of CPG impact on referral and treatment patterns for neoadjuvant chemotherapy in bladder cancer

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5077-5077

2008

Volltextzugriff (PDF)

Using liquid biopsy to assess the genomic landscape of metastatic urothelial carcinoma

European urology supplements : official journal of the European Association of Urology, 2017-03, Vol.16 (3), p.e677-e678

2017

Volltextzugriff (PDF)

A phase II study of sunitinib (SU) for maintenance therapy in metastatic castration-resistant prostate cancer (mCRPC) after response to docetaxel (D)

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.151-151

2011

Volltextzugriff (PDF)

774 ARV7 detected by a novel whole-blood RT-PCR assay correlates with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI)

European urology supplements : official journal of the European Association of Urology, 2016-03, Vol.15 (3), p.e774-e774

2016

Volltextzugriff (PDF)

Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis

Clinical chemistry (Baltimore, Md.), 2005-08, Vol.51 (8), p.1525-1528

2005

Volltextzugriff (PDF)

The neoadjuvant management of bladder cancer in Canada: A survey of genitourinary medical oncologists

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.285-285

2011

Volltextzugriff (PDF)

1149 Non-invasive characterization of metastatic urothelial carcinoma by next-generation sequencing of cell free DNA

European urology supplements : official journal of the European Association of Urology, 2016-03, Vol.15 (3), p.e1149-e1149a

2016

Volltextzugriff (PDF)

A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3014-3014

2011

Volltextzugriff (PDF)

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis

European urology focus, 2019-03, Vol.5 (2), p.242-249

2019

Volltextzugriff (PDF)

A phase II study of patupilone in patients (pts) with metastatic castration- resistant prostate cancer (CRPC) who have progressed after docetaxel

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.5139-5139

2009

Volltextzugriff (PDF)

Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.5012-5012

2009

Volltextzugriff (PDF)

Clinical outcome of metastatic melanoma involving the CNS with or without (w/o) intracranial hemorrhage (IHC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.8577-8577

2007

Volltextzugriff (PDF)

A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1 st -line docetaxel therapy

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5002-5002

2008

Volltextzugriff (PDF)

A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5166-5166

2008

Volltextzugriff (PDF)

A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5069-5069

2007

Volltextzugriff (PDF)

Preclinical evidence that chemotherapy for prostate cancer should be given at the same time as androgen withdrawal

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.4617-4617

2005

Volltextzugriff (PDF)

Significance of insulin-like growth factor binding protein-2 in the prognosis of breast cancer and promotion of accelerated growth and chemo-resistance in MDAMB-231 breast cancer model

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.542-542

2005

Volltextzugriff (PDF)

A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a

Annals of oncology, 2012-01, Vol.23 (1), p.53

2012

Volltextzugriff (PDF)

26 – 50 von 75

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(73)

Publikationsform

Artikel
(74)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Humans
(30)
Life Sciences & Biomedicine
(27)
Male
(21)
Middle Aged
(19)
Female
(17)
Aged
(16)
Oncology
(14)
Aged, 80 And Over
(11)
Adult
(9)
Antineoplastic Agents - Therapeutic Use
(7)
Urology
(7)
Biomarkers
(6)
Hematology, Oncology And Palliative Medicine
(6)
Sensitivity And Specificity
(6)
Urology & Nephrology
(6)
Urothelial Carcinoma
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Cancer
(5)
Carcinoma, Transitional Cell - Drug Therapy
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis

A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

7170 Clinical practice guideline impact on referral and treatment rates of neoadjuvant chemotherapy for muscle-invasive bladder cancer: a comparative analysis between two Canadian tertiary care centres

Cost of care for prostate cancer patients: An observational cohort study comparing clinical trials to standard care

7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC)

A randomized, double-blind, placebo-controlled, phase 3 trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 genetic alterations: PROOF 302

Measurable Absolute Basophil Count is Associated with Progression to Muscle Invasive Disease in Patients with High-Grade Non-Muscle Invasive Bladder Cancer

Do clinical practice guidelines (CPGs) change clinical practice? An analysis of CPG impact on referral and treatment patterns for neoadjuvant chemotherapy in bladder cancer

Using liquid biopsy to assess the genomic landscape of metastatic urothelial carcinoma

A phase II study of sunitinib (SU) for maintenance therapy in metastatic castration-resistant prostate cancer (mCRPC) after response to docetaxel (D)

774 ARV7 detected by a novel whole-blood RT-PCR assay correlates with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI)

Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis

The neoadjuvant management of bladder cancer in Canada: A survey of genitourinary medical oncologists

1149 Non-invasive characterization of metastatic urothelial carcinoma by next-generation sequencing of cell free DNA

A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis

A phase II study of patupilone in patients (pts) with metastatic castration- resistant prostate cancer (CRPC) who have progressed after docetaxel

Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer

Clinical outcome of metastatic melanoma involving the CNS with or without (w/o) intracranial hemorrhage (IHC)

A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1 st -line docetaxel therapy

A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel

A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC)

Preclinical evidence that chemotherapy for prostate cancer should be given at the same time as androgen withdrawal

Significance of insulin-like growth factor binding protein-2 in the prognosis of breast cancer and promotion of accelerated growth and chemo-resistance in MDAMB-231 breast cancer model

A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a

Suchergebnisse filtern